Posted by Michael Wonder on 15 Jan 2020
Health Canada approves Astellas' Xospata (gilteritinib) for patients with relapsed or refractory acute myeloid leukaemia with a FLT3 mutation
14 January 2020 - Xospata is the first and only targeted treatment approved by Health Canada for patients with relapsed or refractory acute myeloid leukaemia with a FLT3 mutation.
Astellas announced that Health Canada has approved the oral once-daily therapy Xospata (gilteritinib) for the treatment of adult patients with relapsed or refractory acute myeloid leukaemia (AML) with a FLT3 mutation. Gilteritinib has the potential to improve treatment outcomes for AML patients with two forms of the most common mutation—FLT3 internal tandem duplication and FLT3 tyrosine kinase domain mutation.
Health Canada's approval of gilteritinib is based on results from the Phase 3 ADMIRAL trial, which investigated gilteritinib versus salvage chemotherapy in patients with relapsed or refractory FLT3 mutated AML.
